{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:08:12Z","timestamp":1793689692975,"version":"4.5.1"},"reference-count":151,"publisher":"The Japanese Society for Medical Mycology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3314\/mmj.16-00006","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T22:20:17Z","timestamp":1480371617000},"page":"E93-E110","source":"Crossref","is-referenced-by-count":51,"title":["Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis"],"prefix":"10.3314","volume":"57","author":[{"given":"Hideyo","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Teikyo University Institute of Medical Mycology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1842","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Zaias N: Onychomycosis. Dermatol Clin 3: 445-460, 1985.","DOI":"10.1016\/S0733-8635(18)30884-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Andes J, Achten G: Onychomycosis. Int J Dermatol 26: 481-490, 1987.","DOI":"10.1111\/j.1365-4362.1987.tb02287.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Elewski BE: Onychomycosis: treatment, quality of life, and economic issues. Am J Clin Dermatol 1: 19-26, 2000.","DOI":"10.2165\/00128071-200001010-00002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Phillips P: New drugs for the nail fungus prevalent in elderly. JAMA 276: 12-13, 1996.","DOI":"10.1001\/jama.1996.03540010014007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Schlefman BS: Onychomycosis: a compendium of facts and a clinical experience. J Foot Ankle Surg 38: 290-302, 1999.","DOI":"10.1016\/S1067-2516(99)80072-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, Shear NH, De Doncker P, Daniel CR 3rd, Elewski BE: Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 36: 395-402, 1997.","DOI":"10.1016\/S0190-9622(97)80215-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ungpakorn R, Lohaprathan S, Reangchainam S: Prevalence of foot diseases in outpatients attending the Institute of Dermatology, Bangkok, Thailand. Clin Exp Dermatol 29: 87-90, 2004.","DOI":"10.1111\/j.1365-2230.2004.01446.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Pierard G: Onychomycosis and other superficial fungal infections of the foot in the elderly: A pan-European survey. Dermatology 202: 220-224, 2001.","DOI":"10.1159\/000051640"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Weinberg JM, Vataie J, Scheinfeld NS: Skin infections in the elderly: diagnosis and management. Dermatol Clin 22: 51-61, 2004.","DOI":"10.1016\/S0733-8635(03)00107-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Singh G, Haneef NS, Uday A: Nail changes and disorders among the elderly. Indian J Dermatol Venereol Leprol 71: 386-392, 2005.","DOI":"10.4103\/0378-6323.18941"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Gupta AK: Onychomycosis in the elderly. Drugs Aging 16: 397-407, 2006.","DOI":"10.2165\/00002512-200016060-00002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Amane S, Chtourou O, Chedi A, Triki S, Belhaj S, Kaouech E, Kallel K, Chaker E: Onychomycosis in the elderly. Ann Dermatol Venereol 134: 743-747, 2007.","DOI":"10.1016\/S0151-9638(07)92529-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Dias N, Santos C, Portela M, Lima N: Toenail onychomycosis in a Portuguese geriatric population. Mycopathologia 172: 1807-1821, 2011.","DOI":"10.1007\/s11046-011-9402-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Baran R: The nail in the elderly. Clin Dermatol 29: 54-60, 2011.","DOI":"10.1016\/j.clindermatol.2010.07.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Szepietowski JC, Reich A, Garlowska E, Kulig M, Baran E; Onychomycosis Epidemiology Study Group: Factors influencing co-existence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol 142: 1249-1284, 2006.","DOI":"10.1001\/archderm.142.10.1279"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Watanabe S, Harada T, Hiruma M, Iozumi K, Katoh T, Mochizuki T, Naka W; Japan Foot Week Group: Epidemiological survey of foot diseases in Japan: Results of 30,000 foot checks by dermatologists. J Dermatol 37: 397-406, 2010.","DOI":"10.1111\/j.1346-8138.2009.00741.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Welsh O, Vera-Cabrera L, Welsh E: Onychomycosis. Clin Dermatol 28: 151-159, 2010.","DOI":"10.1016\/j.clindermatol.2009.12.006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Drake LA: Impact of onychomycosis on quality of life. J Am Pod Med Assoc 87: 507-511, 1997.","DOI":"10.7547\/87507315-87-11-507"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Elewski BE: The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 36: 745-756, 1997.","DOI":"10.1046\/j.1365-4362.1997.00163.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Whittman LR, Hay RJ: The impact of onychomycosis on quality of life. Clin Exp Dermatol 22: 87-89, 1997.","DOI":"10.1111\/j.1365-2230.1997.tb02626.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lubeck DP: Measuring health related quality of life on onychomycosis. J Am Acad Dermatol 38: 564-568, 1998.","DOI":"10.1016\/S0190-9622(98)70487-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Walshaw EM, Foster JK, Cham PM, Grill JP, Chen SC: Nail-QoL: a quality of life instrument for onychomycosis. Int J Dermatol 46: 1279-1286, 2007.","DOI":"10.1111\/j.1365-4632.2007.03362.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Reich A, Szepietowski JC: Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 12: 313-320, 2011.","DOI":"10.2165\/11592120-000000000-00000"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25) Shemer A: Update: medical treatment of onychomycosis. Dermatol Ther 25: 582-593, 2012.","DOI":"10.1111\/j.1529-8019.2012.01551.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26) Grover C, Khurana A: An update on treatment of onychomycosis. Mycoses 55: 541-551, 2012.","DOI":"10.1111\/j.1439-0507.2012.02199.x"},{"key":"26","unstructured":"27) Haneke E: Fungal infections of the nail: nail disease. Semin Dermatol 10: 41-53, 1991."},{"key":"27","doi-asserted-by":"crossref","unstructured":"28) Midgley GM, Moore MK: Mycology of nail disorders. J Am Acad Dermatol 31: S68-S74, 1994.","DOI":"10.1016\/S0190-9622(08)81272-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29) Fragner P: Mykoflora der Onychomykosen. Mykosen 9: 29-34, 1966.","DOI":"10.1111\/j.1439-0507.1966.tb02659.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30) Svejgaard EL, Nilsson J: Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 47: 131-135, 2004.","DOI":"10.1111\/j.1439-0507.2004.00968.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31) Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC: Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists&rsquo; offices in Ontario, Canada- a multicenter survey of 2001 patients. Int J Dermatol 36: 783-787, 1997.","DOI":"10.1046\/j.1365-4362.1997.00349.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32) Foster KW, Ghannoum MA, Elewski BE: Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 50: 748-752, 2004.","DOI":"10.1016\/S0190-9622(03)02117-0"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33) Yoo JY, Suh MK, Ha GY, Kim H: A clinical and mycological study of onychomycosis in the elderly over 10 years (2001-2010). Korean J Med Mycol 19: 83-92, 2014.","DOI":"10.17966\/kjmm.2014.19.4.83"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34) Sei Y and members of the Epidemiological Investigation Committee for Human Mycoses in the Japanese Society for Medical Mycology: 2006 Epidemiological survey of dermatomycoses in Japan. Med Mycol J 53: 185-192, 2012 [Japanese article with English abstract].","DOI":"10.3314\/mmj.53.185"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35) Sei Y and members of the Epidemiological Investigation Committee for Human Mycoses in the Japanese Society for Medical Mycology: 2011 Epidemiological survey of dermatomycoses in Japan. Med Mycol J 56: J129-J135, 2014 [Japanese article with English abstract].","DOI":"10.3314\/mmj.56.J129"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36) Aghamirian MR, Ghiasian SA: Onychomycosis in Iran: epidemiology, causative agents and clinical features. Jpn J Med Mycol 51: 23-29, 2010.","DOI":"10.3314\/jjmm.51.23"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37) El Sayed F, Ammoury A, Haybe RF, Dhaybi R: Onychomycosis in Lebanon: a mycological survey of 772 patients. Mycoses 49: 216-219, 2006.","DOI":"10.1111\/j.1439-0507.2006.01224.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38) Al Sogar SM, Moawad MK, Al-Humaidan YM: Fungal infections as a cause of skin disease in the eastern province of Saudi Arabia: prevailing fungi and pattern of infection. Mycoses 34: 333-337, 1991.","DOI":"10.1111\/j.1439-0507.1991.tb00672.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39) Ellabib MS, Agaj M, Khalifa Z, Kavanagh K: Yeasts of the genus <I>Candida<\/I> are the dominant cause of onychomycosis in Libyan women but not men: results of a 2-year surveillance study. Br J Dermatol 146: 1038-1041, 2002.","DOI":"10.1046\/j.1365-2133.2002.04688.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40) Godoy-Martinez P, Nunes FG, Tomimori-Yamashita J, Urrutia M, Zaror L, Silva V, Fischman O: Onychomycosis in S&atilde;o Paulo, Brazil. Mycopathologia 163: 111-116, 2009.","DOI":"10.1007\/s11046-009-9209-5"},{"key":"40","unstructured":"41) Jesudanam TM, Rao GR, Lakshmi DJ, Kumari GR: Onychomycosis: a significant medical problem. Indian J Dermatol Venereol Leprol 68: 326-329, 2002."},{"key":"41","doi-asserted-by":"crossref","unstructured":"42) Bramono K, Budimulja U: Epidemiology of onychomycosis in Indonesia: data obtained from three individual studies. Jpn J Med Mycol 46: 171-176, 2005.","DOI":"10.3314\/jjmm.46.171"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43) Bokhari MA, Hussian I, Jahangir M, Haroon TS, Aman S, Khurshid K: Onychomycosis in Lahore, Pakistan. Int J Dermatol 38: 591-595, 1999.","DOI":"10.1046\/j.1365-4362.1999.00768.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44) Roberts DT, Taylor WD, Boyle J: Guidelines for treatments of onychomycosis. Br J Dermatol 148: 402-410, 2003.","DOI":"10.1046\/j.1365-2133.2003.05242.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45) Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 11: 415-429, 1998.","DOI":"10.1128\/CMR.11.3.415"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46) Evans EG: Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 38: S32-S36, 1998.","DOI":"10.1016\/S0190-9622(98)70481-5"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47) Vender RB, Lynde CW, Poulin Y: Prevalence and epidemiology of onychomycosis. J Cutan Med Surg 10 (Suppl 2): S28-S33, 2006.","DOI":"10.2310\/7750.2006.00056"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48) Koussidou T, Devliotou-Panagiotidou D, Karakatsanis D, Minas A, Mourellou O, Samara K: Onychomycosis in Northern Greece during 1994-1998. Mycoses 45: 29-37, 2002.","DOI":"10.1046\/j.1439-0507.2002.00705.x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49) Greer DL: Evolving role of nondermatophytes in onychomycosis. Int J Dermatol 34: 521-524, 1995.","DOI":"10.1111\/j.1365-4362.1995.tb02942.x"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50) Baran R, Kaoukhov A: Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 19: 21-29, 2005.","DOI":"10.1111\/j.1468-3083.2004.00988.x"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51) Tosti A, Piraccini BA, Lorenzi S: Onychomycosis caused by nondermatophytic molds: Clinical features and response to treatment of 59 cases. J Am Acad Dermatol 42: 217-224, 2000.","DOI":"10.1016\/S0190-9622(00)90129-4"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52) Moreno G, Arenas R: Other fungi causing onychomycosis. Clin Dermatol 28: 160-163, 2010.","DOI":"10.1016\/j.clindermatol.2009.12.009"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53) Niewerth M, Korting HC: Management of onychomycosis. Drugs 58: 285-296, 1999.","DOI":"10.2165\/00003495-199958020-00005"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54) Drake LA, Patrick DL, Fleckman P, Andr J, Baran R, Haneke E, Sap&egrave;de C, Tosti A: The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 41: 189-196, 1999.","DOI":"10.1016\/S0190-9622(99)70047-2"},{"key":"54","doi-asserted-by":"crossref","unstructured":"55) Tan JS, Joseph WS: Common fungal infections of the feet in patients with diabetes mellitus. Drugs Aging 21: 101-112, 2004.","DOI":"10.2165\/00002512-200421020-00003"},{"key":"55","doi-asserted-by":"crossref","unstructured":"56) Gupta AK, Shear NH: A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety 22: 33-52, 2000.","DOI":"10.2165\/00002018-200022010-00004"},{"key":"56","unstructured":"57) Gupta AK, Uro M, Cooper EA: Onychomycosis therapy: past, present, future. J Drugs Dermatol 9: 1109-1113, 2010."},{"key":"57","doi-asserted-by":"crossref","unstructured":"58) Grover C, Khurana A: An update on treatment of onychomycosis. Mycoses 55: 541-551, 2012.","DOI":"10.1111\/j.1439-0507.2012.02199.x"},{"key":"58","doi-asserted-by":"crossref","unstructured":"59) Gupta AK, Simpson FC: New therapeutic options for onychomycosis. Expert Opin Pharmacother 13: 1131-1142, 2012.","DOI":"10.1517\/14656566.2012.681779"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60) de Sa DC, Lamas APB, Tosti A: Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol 15: 17-36, 2014.","DOI":"10.1007\/s40257-013-0056-2"},{"key":"60","doi-asserted-by":"crossref","unstructured":"61) Gupta AK, Simpson FC: Investigational drugs for onychomycosis. Expert Opin Investig Drugs 23: 97-106, 2014.","DOI":"10.1517\/13543784.2013.840289"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62) Arrese JE, Pierard-Franchmont C, Pierard GE: Facing up to the diagnostic uncertainty and management of onychomycosis. Int J Dermatol 38: S1-S6, 1999.","DOI":"10.1046\/j.1365-4362.1999.00007.x"},{"key":"62","doi-asserted-by":"crossref","unstructured":"63) Arrese JE, Pierard-Franchmont C, Pierard GE: A plea to bridge the gap between antifungal and onychomycosis management. Am J Clin Dermatol 2: 281-284, 2001.","DOI":"10.2165\/00128071-200102050-00002"},{"key":"63","doi-asserted-by":"crossref","unstructured":"64) Arrese JE, Pierard GE: Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 207: 255-260, 2003.","DOI":"10.1159\/000073086"},{"key":"64","doi-asserted-by":"crossref","unstructured":"65) Gupta AK, Cooper EA: Update in antifungal therapy of dermatophytosis. Mycopathologia 166: 353-367, 2008.","DOI":"10.1007\/s11046-008-9109-0"},{"key":"65","doi-asserted-by":"crossref","unstructured":"66) Gupta AK, Ryder JE, Johnson AM: Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 150: 537-544, 2004.","DOI":"10.1046\/j.1365-2133.2003.05728.x"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67) Sigurgeirsson B, Billstein S, Rantanen T, Ruzicka T, Di Ponzo E, Vermeer BJ, Goodfield MJ, Evans EG: L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil &reg;) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis. Br J Dermatol 141 (Suppl 56): 5-14, 1999.","DOI":"10.1046\/j.1365-2133.1999.00008.x"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68) Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG: Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138: 353-357, 2002.","DOI":"10.1001\/archderm.138.3.353"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69) Heikkil&auml; H, Stubb S: Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol 146: 250-252, 2002.","DOI":"10.1046\/j.1365-2133.2002.04639.x"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70) Gupta AK, Lynch LE: Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis 74: 10-15, 2004.","DOI":"10.1002\/lt.20258"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71) Piraccini BM, Sisti A, Tosti A: Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 62: 411-414, 2010.","DOI":"10.1016\/j.jaad.2009.04.062"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72) Tsuruoka A, Kaku Y, Kakinuma H, Tsukada I, Yanagisawa M, Nara K, Naito T: Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives. Chem Pharm Bull 46: 623-630, 1998.","DOI":"10.1248\/cpb.46.623"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73) Ueda Y, Matiskella JD, Golik J, et al: Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. Bioorg Med Chem Lett 13: 3669-3672, 2003.","DOI":"10.1016\/j.bmcl.2003.08.029"},{"key":"73","doi-asserted-by":"crossref","unstructured":"74) T&uuml;rel &Ouml;: Newer antifungal agents. Expert Rev Anti Infect Ther 9: 325-338, 2011.","DOI":"10.1586\/eri.10.163"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75) Groll AH, Mickiene D, Petraitis V, Petraitienne R, Kelaher A, Sarafandi A, Wuerthwein G, Bacher J, Walsh TJ: Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J Antimicrob Chemother 56: 899-907, 2005.","DOI":"10.1093\/jac\/dki287"},{"key":"75","doi-asserted-by":"crossref","unstructured":"76) Petraitiene R, Petraitis V, Lyman CA, Groll AH, Mickiene D, Peter J, Bacher J, Roussillon K, Hemmings M, Armstrong D, Avila NA, Walsh TJ: Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 48: 1188-1196, 2004.","DOI":"10.1128\/AAC.48.4.1188-1196.2004"},{"key":"76","doi-asserted-by":"crossref","unstructured":"77) Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein T, Groll AH, Bacher J, Avila NA, Walsh TJ: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 187: 1834-1843, 2003.","DOI":"10.1086\/375420"},{"key":"77","unstructured":"78) E1224 Fifth Edition Global Investigator Brochure March 29, 2013."},{"key":"78","doi-asserted-by":"crossref","unstructured":"79) Sheehan DJ, Hitchcock CA, Sibley CM: Current and emerging azole antifungal agents. Clin Microbiol Rev 12: 40-79, 1999.","DOI":"10.1128\/CMR.12.1.40"},{"key":"79","doi-asserted-by":"crossref","unstructured":"80) Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12: 501-517, 1999.","DOI":"10.1128\/CMR.12.4.501"},{"key":"80","doi-asserted-by":"crossref","unstructured":"81) Lamb D, Kelly D, Kelly S: Molecular aspects of azole antifungal action and resistance. Drug Resist Update 2: 390-402, 1999.","DOI":"10.1054\/drup.1999.0112"},{"key":"81","doi-asserted-by":"crossref","unstructured":"82) Fran&ccedil;ois IE, Aerts AM, Cammue BP, Thevissen K: Currently used antimycotics: spectrum, mode of action and resistance occurrence. Curr Drug Targets 6: 895-907, 2005.","DOI":"10.2174\/138945005774912744"},{"key":"82","doi-asserted-by":"crossref","unstructured":"84) Fera MT, La Camera E, De Sarro A: New triazoles and echinocandins: mode of action, <I>in vitro<\/I> activity and mechanisms of resistance. Expert Rev Anti Infect Ther 7: 981-988, 2009.","DOI":"10.1586\/eri.09.67"},{"key":"83","doi-asserted-by":"crossref","unstructured":"86) Kelly SL, Lamb DC, Baldwin BC, Corran AJ, Kelly DE: Characterization of <I>Saccharomyces cerevisiae<\/I> CYP61, sterol &delta; 22-desaturase, and inhibition by azole antifungal agents. J Biol Chem 272: 9986-9988, 1997.","DOI":"10.1074\/jbc.272.15.9986"},{"key":"84","doi-asserted-by":"crossref","unstructured":"87) Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PA: Mutation in cytochrome P450-dependent 14&alpha;-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans 18: 56-59, 1990.","DOI":"10.1042\/bst0180056"},{"key":"85","doi-asserted-by":"crossref","unstructured":"88) Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM: Three-dimensional models of wild-type and mutated forms of cytochrome P450 14&alpha;-sterol demethylases from <I>Aspergillus fumigatus<\/I> and <I>Candida albicans<\/I> provide insights into posaconazole binding. Antimicrob Agents Chemother 48: 568-574, 2004.","DOI":"10.1128\/AAC.48.2.568-574.2004"},{"key":"86","doi-asserted-by":"crossref","unstructured":"89) Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K: <I>In vitro<\/I> and <I>in vivo<\/I> antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 40: 2237-2242, 1996.","DOI":"10.1128\/AAC.40.10.2237"},{"key":"87","doi-asserted-by":"crossref","unstructured":"91) Diekema DJ, Pfaller MA, Messer SA, Houston A, Hollis RJ, Doern GV, Jones RN: <I>In vitro<\/I> activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of <I>Candida<\/I> species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob Agents Chemother 43: 2236-2239, 1999.","DOI":"10.1128\/AAC.43.9.2236"},{"key":"88","doi-asserted-by":"crossref","unstructured":"92) Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ: International surveillance of bloodstream infections due to <I>Candida<\/I> species in the European SENTRY Program: species distribution and antifungal susceptibility including investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 35: 19-25, 1999.","DOI":"10.1016\/S0732-8893(99)00046-2"},{"key":"89","doi-asserted-by":"crossref","unstructured":"93) Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit A, Hollis RJ, Messer SA; SENTRY Participant Group: International surveillance of bloodstream infections due to <I>Candida<\/I> species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 39: 3254-3259, 2001.","DOI":"10.1128\/JCM.39.9.3254-3259.2001"},{"key":"90","doi-asserted-by":"crossref","unstructured":"94) Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ and the SENTRY Participants Group: Trends in antifungal susceptibility of <I>Candida<\/I> spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40: 852-856, 2002.","DOI":"10.1128\/JCM.40.3.852-856.2002"},{"key":"91","doi-asserted-by":"crossref","unstructured":"95) Messer SA, Jones RN, Fritsche TR: International surveillance of <I>Candida<\/I> spp. and <I>Aspergillus<\/I> spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 44: 1782-1787, 2006.","DOI":"10.1128\/JCM.44.5.1782-1787.2006"},{"key":"92","doi-asserted-by":"crossref","unstructured":"96) Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA: <I>In vitro<\/I> susceptibilities of <I>Candida<\/I> bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 42: 3242-3244, 1998.","DOI":"10.1128\/AAC.42.12.3242"},{"key":"93","doi-asserted-by":"crossref","unstructured":"97) Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ: <I>In vitro<\/I> activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of <I>Candida<\/I> spp. Antimicrob Agents Chemother 46: 1723-1727, 2002.","DOI":"10.1128\/AAC.46.6.1723-1727.2002"},{"key":"94","doi-asserted-by":"crossref","unstructured":"98) Gupta AK, Kohli Y, Batra R: <I>In vitro<\/I> activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol 43: 179-185, 2005.","DOI":"10.1080\/13693780410001731583"},{"key":"95","doi-asserted-by":"crossref","unstructured":"99) St-Germain G, Laverdi&egrave;re M, Pelletier R, Ren&eacute; P, Bourgault AM, Lemieux C, Libman M: Epidemiology and antifungal susceptibility of bloodstream <I>Candida<\/I> isolates in Quebec: reports on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 19: 55-62, 2008.","DOI":"10.1155\/2008\/634046"},{"key":"96","doi-asserted-by":"crossref","unstructured":"100) Gonz&aacute;lez GM, Elizondo M, Ayala J: Trends in species distribution and susceptibility of bloodstream isolates of <I>Candida<\/I> collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol 46: 2902-2905, 2008.","DOI":"10.1128\/JCM.00937-08"},{"key":"97","doi-asserted-by":"crossref","unstructured":"101) Yamaguchi H, Ikeda F, Iyoda T, Suzuki M, Mikawa T: <I>In vitro<\/I> antifungal activity of ravuconazole against isolates of dermatophytes and <I>Candida<\/I> species from patients with dermatomycoses: comparison with the two oral antifungal drugs approved for the systemic treatment of intractable forms of the diseases. Med Mycol J 55: J157-J163, 2014 [Japanese article with English abstract].","DOI":"10.3314\/mmj.55.J157"},{"key":"98","doi-asserted-by":"crossref","unstructured":"102) Laverdiere M, Hoban D, Restieri C, Habel F: <I>In vitro<\/I> activity of three new triazoles and one echinocandin against <I>Candida<\/I> bloodstream isolates from cancer patients. J Antimicrob Chemother 50: 119-123, 2002.","DOI":"10.1093\/jac\/dkf074"},{"key":"99","doi-asserted-by":"crossref","unstructured":"103) Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ: Geographic variation in the susceptibilities of invasive isolates of <I>Candida glabrata<\/I> to seven systematically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 42: 3142-3146, 2004.","DOI":"10.1128\/JCM.42.7.3142-3146.2004"},{"key":"100","doi-asserted-by":"crossref","unstructured":"104) Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN: <I>In vitro<\/I> susceptibilities of rare <I>Candida<\/I> bloodstream isolates to ravucoonazole and three comparative antifungal agents. Diag Microbiol Infect Dis 48: 101-105, 2004.","DOI":"10.1016\/j.diagmicrobio.2003.09.009"},{"key":"101","doi-asserted-by":"crossref","unstructured":"105) Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, Coleman DC, Soll DR: <I>In vitro<\/I> susceptibilities of <I>Candida dubliniensis<\/I> isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 37: 870-872, 1999.","DOI":"10.1128\/JCM.37.3.870-872.1999"},{"key":"102","doi-asserted-by":"crossref","unstructured":"106) Fung-Tomc JC, White TC, Minassian B, Huczko E, Bonner DP: <I>In vitro<\/I> antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diag Microbiol Infect Dis 35: 163-167, 1999.","DOI":"10.1016\/S0732-8893(99)00063-2"},{"key":"103","doi-asserted-by":"crossref","unstructured":"107) Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL: <I>In vitro<\/I> activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother 48: 3107-3111, 2004.","DOI":"10.1128\/AAC.48.8.3107-3111.2004"},{"key":"104","doi-asserted-by":"crossref","unstructured":"108) Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ: Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of <I>Candida<\/I> spp. J Clin Microbiol 42: 3137-3141, 2004.","DOI":"10.1128\/JCM.42.7.3137-3141.2004"},{"key":"105","doi-asserted-by":"crossref","unstructured":"109) Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RA, Jones RN: <I>In vitro<\/I> activities of ravuconazole (BMS-207147) against 541 clinical isolates of <I>Cryptococcus neoformans<\/I>. Antimicrob Agents Chemother 44: 2883-2886, 2000.","DOI":"10.1128\/AAC.44.10.2883-2886.2000"},{"key":"106","doi-asserted-by":"crossref","unstructured":"110) Yildiran ST, Saracli MA, Fothergill AW, Rinaldi MG: <I>In vitro<\/I> susceptibility of environmental <I>Cryptococcus neoformans<\/I> variety <I>neoformans<\/I> isolates from ssTurkey to six antifungal agents, including SCH56592 and voriconazole. Eur J Clin Microbiol Infect Dis 19: 317-319, 2000.","DOI":"10.1007\/s100960050484"},{"key":"107","doi-asserted-by":"crossref","unstructured":"111) Trilles L, Fern&aacute;ndez-Torres B, Laz&eacute;ra MS, Wanke B, Guarro J: <I>In vitro<\/I> antifungal susceptibility of <I>Cryptococcus gattii<\/I>. J Clin Microbiol 42: 4815-4817, 2004.","DOI":"10.1128\/JCM.42.10.4815-4817.2004"},{"key":"108","doi-asserted-by":"crossref","unstructured":"112) Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV, Diekema DJ: Global trends in the antifungal susceptibility of <I>Cryptococcus neoformans<\/I> (1990 to 2004). J Clin Microbiol 43: 2163-2167, 2005.","DOI":"10.1128\/JCM.43.5.2163-2167.2005"},{"key":"109","doi-asserted-by":"crossref","unstructured":"113) Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH: <I>In vitro<\/I> antifungal susceptibilities in <I>Trichosporon<\/I> species. Antimicrob Agents Chemother 46: 1144-1146, 2002.","DOI":"10.1128\/AAC.46.4.1144-1146.2002"},{"key":"110","doi-asserted-by":"crossref","unstructured":"114) Serena C, Pastor FJ, Ortoneda M, Capilla J, Noland N, Guarro J: <I>In vitro<\/I> antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 48: 2724-2726, 2004.","DOI":"10.1128\/AAC.48.7.2724-2726.2004"},{"key":"111","doi-asserted-by":"crossref","unstructured":"115) Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M: Susceptibility profile of 29 clinical isolates of <I>Rhodotorula<\/I> spp. and literature review. J Antimicrob Chemother 55: 312-316, 2005.","DOI":"10.1093\/jac\/dki020"},{"key":"112","doi-asserted-by":"crossref","unstructured":"116) Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA: Activities of available and investigational antifungal agents against <I>Rhodotorula<\/I> species. J Clin Microbiol 43: 476-478, 2005.","DOI":"10.1128\/JCM.43.1.476-478.2005"},{"key":"113","doi-asserted-by":"crossref","unstructured":"117) Gonz&aacute;lez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D: <I>In vitro<\/I> activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 43: 281-284, 2005.","DOI":"10.1080\/13693780500088416"},{"key":"114","doi-asserted-by":"crossref","unstructured":"118) Ahmed SA, Kloezen W, Duncason F, Zijlstra EE, de Hoog GS, Fahal AH, van de Sande WW: <I>Madurella mycetomatis<\/I> is highly susceptible to ravuconazole. PloS Negl Trop Dis 8: e2942, 2014.","DOI":"10.1371\/journal.pntd.0002942"},{"key":"115","doi-asserted-by":"crossref","unstructured":"119) Serena C, Ortoneda M, Capilla J, Pastor FJ, Sutton DA, Rinaldi MG, Guarro J: <I>In vitro<\/I> activities of new antifungal agents against <I>Chaetomium<\/I> spp. and inoculum standardization. Antimicrob Agents Chemother 47: 3161-3164, 2003.","DOI":"10.1128\/AAC.47.10.3161-3164.2003"},{"key":"116","doi-asserted-by":"crossref","unstructured":"120) Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL: <I>In vitro<\/I> activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 49: 5136-5138, 2005.","DOI":"10.1128\/AAC.49.12.5136-5138.2005"},{"key":"117","doi-asserted-by":"crossref","unstructured":"121) Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J: <I>In vitro<\/I> activity of ravuconazole against <I>Zygomycetes, Scedosporium<\/I> and <I>Fusarium<\/I> isolates. Clin Microbiol Infect 9: 1250-1252, 2003.","DOI":"10.1111\/j.1469-0691.2003.00755.x"},{"key":"118","doi-asserted-by":"crossref","unstructured":"122) Gilgado F, Serena C, Cano J, Gen&eacute; J, Guarro J: Antifungal susceptibilities of the <I>Pseudallescheria boydii<\/I> complex. Antimicrob Agents Chemother 50: 4211-4213, 2006.","DOI":"10.1128\/AAC.00981-06"},{"key":"119","doi-asserted-by":"crossref","unstructured":"123) Carrillo AJ, Guarro J: <I>In vitro<\/I> activities of four novel triazoles against <I>Scedosporium<\/I> spp. Antimicrob Agents Chemother 45: 2151-2153, 2001.","DOI":"10.1128\/AAC.45.7.2151-2153.2001"},{"key":"120","doi-asserted-by":"crossref","unstructured":"124) Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41: 3623-3626, 2003.","DOI":"10.1128\/JCM.41.8.3623-3626.2003"},{"key":"121","doi-asserted-by":"crossref","unstructured":"125) Pfaller MA, Messer SA, Hollis RJ, Jones RN, and the Sentry Participants Group: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of <I>Aspergillus<\/I> spp. and other filamentous fungi: report from SENTRY Antimicrobiol Surveillance Program, 2000. Antimicrob Agents Chemother 46: 1032-1037, 2002.","DOI":"10.1128\/AAC.46.4.1032-1037.2002"},{"key":"122","doi-asserted-by":"crossref","unstructured":"126) Moore CB, Walls CM, Denning DW: <I>In vitro<\/I> activity of the new triazole BMS-207147 against <I>Aspergillus<\/I> species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 41: 441-443, 2000.","DOI":"10.1128\/AAC.44.2.441-443.2000"},{"key":"123","doi-asserted-by":"crossref","unstructured":"127) Espinel-Ingroff A: Germinated and nongerminated conidial suspensions for testing of susceptibilities of <I>Aspergillus<\/I> spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 45: 605-607, 2001.","DOI":"10.1128\/AAC.45.2.605-607.2001"},{"key":"124","doi-asserted-by":"crossref","unstructured":"128) Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ: Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for <I>Aspergillus<\/I> spp. : NCCLS Collaborative Study. J Clin Microbiol 40: 3204-3208, 2002.","DOI":"10.1128\/JCM.40.9.3204-3208.2002"},{"key":"125","doi-asserted-by":"crossref","unstructured":"129) Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ: <I>In vitro<\/I> survey of triazole cross-resistance among more than 700 clinical isolates of <I>Aspergillus<\/I> species. J Clin Microbiol 46: 2568-2572, 2008.","DOI":"10.1128\/JCM.00535-08"},{"key":"126","doi-asserted-by":"crossref","unstructured":"130) Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruez-Izquierdo A, Monzon A, Cuenca-Estrella M: Epidemiological cutoffs and cross-resistance to azole drugs in <I>Aspergillus fumigatus<\/I>. Antimicrob Agents Chemother 52: 2468-2472, 2008.","DOI":"10.1128\/AAC.00156-08"},{"key":"127","doi-asserted-by":"crossref","unstructured":"131) Mosquera J, Denning DW: Azole cross-resistance in <I>Aspergillus fumigatus<\/I>. Antimicrob Agents Chemother 46: 556-557, 2002.","DOI":"10.1128\/AAC.46.2.556-557.2002"},{"key":"128","doi-asserted-by":"crossref","unstructured":"132) Ortoneda M, Capilla J, Pastor FJ, Pujol I, Yustes C, Serena C, Guarro J: <I>In vitro<\/I> interactions of approved and novel drugs against <I>Paecilomyces<\/I> spp. Antimicrob Agents Chemother 48: 2727-2729, 2004.","DOI":"10.1128\/AAC.48.7.2727-2729.2004"},{"key":"129","doi-asserted-by":"crossref","unstructured":"133) Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH: <I>In vitro<\/I> activities of investigational triazoles against <I>Fusarium species<\/I>: effects of inoculums size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 46: 3298-3300, 2002.","DOI":"10.1128\/AAC.46.10.3298-3300.2002"},{"key":"130","doi-asserted-by":"crossref","unstructured":"134) Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K: Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 40: 2243-2247, 1996.","DOI":"10.1128\/AAC.40.10.2243"},{"key":"131","doi-asserted-by":"crossref","unstructured":"135) Mikamo H, Yin XH, Hayasaki Y, Satoh M, Tamaya T: Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model. Chemotherapy 47: 377-380, 2001.","DOI":"10.1159\/000048546"},{"key":"132","doi-asserted-by":"crossref","unstructured":"136) Clemons KV, Stevens DA: Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob Agents Chemother 2001; 45: 3433-3436.","DOI":"10.1128\/AAC.45.12.3433-3436.2001"},{"key":"133","doi-asserted-by":"crossref","unstructured":"138) Roberts J, Shock K, Marino S, Andriole VT: Efficacies of two new antifungal agents, the triazole revuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 44: 3381-3388, 2000.","DOI":"10.1128\/AAC.44.12.3381-3388.2000"},{"key":"134","doi-asserted-by":"crossref","unstructured":"139) Clemons KV, Martinez M, Calderon L, Stevens DA: Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob Agents Chemother 46: 922-924, 2002.","DOI":"10.1128\/AAC.46.3.922-924.2002"},{"key":"135","unstructured":"140) Arikan S, Rex JH: Ravuconazole. Curr Opin Investig Drugs 3: 555-561, 2002."},{"key":"136","doi-asserted-by":"crossref","unstructured":"141) Mikamo H, Yin XH, Hayasaki Y, Shimamura K, Uesugi N, Fukuyama N, Satoh M, Tamaya T: Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy 48: 7-9, 2002.","DOI":"10.1159\/000048580"},{"key":"137","doi-asserted-by":"crossref","unstructured":"142) Andes D, Marchillo K, Stamstad T, Conklin R: <I>In vivo<\/I> pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47: 1193-1199, 2003.","DOI":"10.1128\/AAC.47.4.1193-1199.2003"},{"key":"138","doi-asserted-by":"crossref","unstructured":"143) Groll AH, Mickiene D, Petraitis V, Petraitiene R, Kelaher A, Sarafandi A, Wuerthwein G, Bacher J, Walsh TJ: Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J Antimicrob Chemother 56: 899-907, 2005.","DOI":"10.1093\/jac\/dki287"},{"key":"139","doi-asserted-by":"crossref","unstructured":"144) De Sarro A, La Camera E, Fera MT: New and investigational triazole agents for the treatment of invasive fungal infections. J Chemother 20: 51-61, 2008.","DOI":"10.1179\/joc.2008.20.6.661"},{"key":"140","doi-asserted-by":"crossref","unstructured":"145) Pasqualotto AC, Denning DW: New and emerging treatments for fungal infections. J Antimicrob Chemother 61 (Suppl 1): i19-i30, 2008.","DOI":"10.1093\/jac\/dkm428"},{"key":"141","doi-asserted-by":"crossref","unstructured":"146) Girmenia C: New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 18: 1279-1295, 2009.","DOI":"10.1517\/13543780903176407"},{"key":"142","doi-asserted-by":"crossref","unstructured":"147) T&uuml;rel &Ouml;: Newer antifungal agents. Expert Rev Anti Infect Ther 9: 325-338, 2011.","DOI":"10.1586\/eri.10.163"},{"key":"143","unstructured":"148) Olsen SJ, Mummaneni V, Rolan P, Norton J, Grasela DM: Ravuconazole single ascending oral dose study in healthy subjects. <I>In<\/I> Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000."},{"key":"144","unstructured":"149) Grasela DM, Olsen SJ, Mummaneni V, et al: Ravuconazole: multiple ascending oral dose study in healthy subjects. <I>In<\/I> Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000."},{"key":"145","unstructured":"150) Marino M, Mummaneni V, Norton J, Hadjilambris O, Pierce P: Ravuconazole exposure-response relationship in HIV+ patients with oropharyngeal candidiasis. <I>In<\/I> Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001."},{"key":"146","unstructured":"151) Lin P, Mickiene D, Roden MM, et al: Pharmacokinetics and safety of ravuconazole for prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. <I>In<\/I> Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005."},{"key":"147","doi-asserted-by":"crossref","unstructured":"153) Gupta AK, Leonardi C, Stoltz RR, Pierce PF: A Phase I\/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol 19: 437-449, 2005.","DOI":"10.1111\/j.1468-3083.2005.01212.x"},{"key":"148","doi-asserted-by":"crossref","unstructured":"154) Yan JH, Marino MR, Smith RA, Kanamaluru V, O&rsquo;Mara EM, Grasela DM: The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J Clin Pharmacol 46: 193-200, 2006.","DOI":"10.1177\/0091270005283462"},{"key":"149","doi-asserted-by":"crossref","unstructured":"155) Mummaneni V, Geraldes M, Hadjilambris O, Ouyang Z, Uderman U, Marino M: Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects. <I>In<\/I> Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000.","DOI":"10.1177\/00912700022009611"},{"key":"150","doi-asserted-by":"crossref","unstructured":"156) Ernst EJ: Investigational antifungal agents. Pharmacotherapy 21: 165S-174S, 2001.","DOI":"10.1592\/phco.21.12.165S.34509"},{"key":"151","unstructured":"157) Beale M, Queiroz-Telles F, Banhegyi D, Li N, Pierce PF: Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. <I>In<\/I> Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001."}],"container-title":["Medical Mycology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/4\/57_16-00006\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T15:21:12Z","timestamp":1601220072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/4\/57_16-00006\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":151,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.16-00006","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}